| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 10/14/2004 | US20040204365 Methods of using cyanovirins to inhibit viral infection |
| 10/14/2004 | US20040204364 Peptides for activation and inhibition of deltaPKC |
| 10/14/2004 | US20040204363 providing a complex containing peptide or protein of interest covalently linked to amino terminal ATP binding domain of a heat shock protein 70 (hsp70) or the carboxyl terminal peptide binding domain of an hsp70, contacting the cell with the complex for entry of the complex into the cell |
| 10/14/2004 | US20040204362 Alpha-conotoxin peptides |
| 10/14/2004 | US20040204361 Kdel receptor inhibitors |
| 10/14/2004 | US20040204360 a nucleotide sequence encoding a protein of the ONECUT family characterized by the presence of a single CUT domain and the presence of an F48M50 dyad in the homeo domain for the treatment or for the prevention of diabetes or cancer, in particular to a genetic/cellular therapy |
| 10/14/2004 | US20040204359 Methods and compositions in treating pain and painful disorders using 16386,15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620 |
| 10/14/2004 | US20040204358 Reducing culling in herd animals growth hormone releasing hormone (GHRH) |
| 10/14/2004 | US20040204356 Treatment of diabetes |
| 10/14/2004 | US20040204351 Soluble proteins that inhibit cytokine signal transduction pathways |
| 10/14/2004 | US20040204350 Disease- associated protein |
| 10/14/2004 | US20040204349 Inducing cytotoxicity in a neoplastic cell comprising: contacting said cell with an amount of a GSSP-2 polypeptide |
| 10/14/2004 | US20040204348 Cyclic peptide ligands that target urokinase plasminogen activator receptor |
| 10/14/2004 | US20040204347 administering an effective amount of an inhibitor of the interaction of glutamate with the alpha -amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptor complex to treat demyelinating disorders |
| 10/14/2004 | US20040204346 Intermediate for preparing glycopeptide derivatives |
| 10/14/2004 | US20040204345 Using recombinant zinc finger proteins; use in human therapeutic applications such as cancer therapy and altering plant phenotypes, including disease resistance, fruit ripening |
| 10/14/2004 | US20040204343 Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| 10/14/2004 | US20040204342 Orthodontic remedies containing |
| 10/14/2004 | US20040204340 administering to the animal an effective amount of a neurotrophic compound having an affinity for a cyclophilin-type immunophilin, wherein the immunophilin exhibits rotamase activity and the neurotrophic compound inhibits the rotamase activity of the immunophilin |
| 10/14/2004 | US20040203157 Transfroming arabidopsis with expression vector coding genes associated with heat, freeze, salt and drought resistance; using ribonucleoproteins to control effivient gene transcription in plants; bioreactors |
| 10/14/2004 | US20040203153 Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made |
| 10/14/2004 | US20040203128 Use of PP2A phosphatase modulators in the treatment of mental disorders |
| 10/14/2004 | US20040203125 recombinant chimera produced using solid phase synthesis; for biosnesors/bioreactors, diagnostic and drugs |
| 10/14/2004 | US20040203118 Polynucleotides and polypeptides of the IFNalpha-14 gene |
| 10/14/2004 | US20040203111 UDP-N-acetylglucosamine: galactose-B1,3-N-acetylgalactosamine-a-R/ (GlcNAc to GalNAc) B1-6 N- acetylglucosaminyltransferase, C2GnT3 |
| 10/14/2004 | US20040203107 Methods and compositions for grafting functional loops into a protein |
| 10/14/2004 | US20040203104 for drug screening enzyme inhibitors; genetic engineering; comprising subjecting the sample to a polymerase chain reaction, a northern hybridization assay or an in situ hybridization assay |
| 10/14/2004 | US20040203102 Antiplasmin cleaving enzyme |
| 10/14/2004 | US20040203101 Brain-associated inhibitor of tissue-type plasminogen activator |
| 10/14/2004 | US20040203099 Conjugate of a transport protein and a protein for modulation of notch signalling |
| 10/14/2004 | US20040203098 Compounds and methods for modulating activation of NF-kappaB |
| 10/14/2004 | US20040203097 Kinases and phosphatases |
| 10/14/2004 | US20040203096 performed in vitro; for treatment of type II glycogen storage disease in mammals, including humans; genetic engineering |
| 10/14/2004 | US20040203092 UDP-N-acetylglucosamine:galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1-6 N-acetylglucosaminyltransferase, C2GnT3 |
| 10/14/2004 | US20040203090 Biodegradable glucosaminemuramyl peptides for apoptosis modulation |
| 10/14/2004 | US20040203087 screening gene expression inhibition via incubating mrna, determining expression in presence of test compound, then comparing levels; gene knockout |
| 10/14/2004 | US20040203066 Identifying modulator of progression elevated gene-3 (PEG-3) for use in treatment and prevention of antitumor/antiproliferative/antisense agents; peptide mimetic |
| 10/14/2004 | US20040203063 Comprises nucleotide sequence coding tumor marker protein for use in diagnosis of prostate cancer |
| 10/14/2004 | US20040203059 Novel human proteases and polynucleotides encoding the same |
| 10/14/2004 | US20040203054 Use of SLIM3 for binding to molecules |
| 10/14/2004 | US20040203026 preferred cleaving conditions include heating in an acceptable buffer for a time ranging between about 16 and 24 hours at a temperature between about 20 degrees C. and about 37 degrees C |
| 10/14/2004 | US20040203022 clinical screening, diagnosis, prognosis, therapy and prophylaxis, as well as for drug screening and drug development using solid phase synthesis; kits |
| 10/14/2004 | US20040203014 Neurotransmisson-associated proteins |
| 10/14/2004 | US20040203001 Methods for identifying human cell lines useful for endogenous gene activation, isolated human cell lines identified thereby, and uses thereof |
| 10/14/2004 | US20040202733 For administering high levels of plant antioxidants to human and mammals; includes drinks such as shakes, bars, capsules, tablets, and soft-gel capsules; high antioxidant activity and very high levels of protein |
| 10/14/2004 | US20040202693 Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem |
| 10/14/2004 | US20040202679 truncated papillomavirus L1 protein consisting of an amino acid sequence having one or more carboxy terminal amino acid residues deleted from a full length L1 amino acid sequence, and amino acid residues from a second protein replacing deleted amino acid residues in the truncated L1 protein. |
| 10/14/2004 | US20040202674 zona pellucida polypeptide, and/or a variant, from a carnivorous mammal, useful in reducing fertility of cats and/or dogs. |
| 10/14/2004 | US20040202664 Prevention of tumors with monoclonal antibodies against neu |
| 10/14/2004 | US20040202663 Therapy for primary and metastatic cancers |
| 10/14/2004 | US20040202662 Humanised antibodies |
| 10/14/2004 | US20040202661 a peptide or derivative capable of binding to the IL-2 beta chain or the monoclonal antibodies produced by H2-8 hybridoma; induces SHC phosphorylation or induces the SHC/MAPK pathway |
| 10/14/2004 | US20040202659 A polypeptide encoded by a nucleic acid that encodes a heavy chain, which is able to bind to GPIIb/IIIa, of a human antibody and comprising a CDR3 region; diagnosis, treatment or prevention of autoimmune thrombocytopenic purpura; modulating blood coagulation |
| 10/14/2004 | US20040202654 gp100-derived polypeptides that contain both a helper T-cell epitope and a cytotoxic T-cell epitope used to induce antitumor responses in melanoma patients |
| 10/14/2004 | US20040202652 Methods and compositions for control of bone formation via modulation of leptin activity |
| 10/14/2004 | US20040202650 Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies |
| 10/14/2004 | US20040202647 T cell line specific for a nitrotyrosine-containing compound; antibody specific for a self-antigen comprising a tyrosine to nitrotyrosine conversion; prevention and treatment of autoimmune diseases, infectious diseases and cancer through the recognition of compounds containing nitrated tyrosine residues |
| 10/14/2004 | US20040202646 Bifunctional glycoproteins having a modified carbohydrate complement and their use in tumor-selective therapy |
| 10/14/2004 | US20040202645 oral or mucosal administration for treating immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease and other inflammatory diseases |
| 10/14/2004 | US20040202641 Recombinant super-compound interferon |
| 10/14/2004 | US20040202616 comprises magnesium stearate for improved storage stability; inhalers |
| 10/14/2004 | DE10313636A1 Verwendung von Wirksubstanzen zur Vorbeuge oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen The use of active substances for the prevention or treatment of viral diseases and Test System for Finding such active substances |
| 10/14/2004 | DE10313341A1 Verwendung von proNGF, insbesondere zur Wundheilung der Cornea und der Haut Use of proNGF, especially for wound healing of the cornea and skin |
| 10/14/2004 | DE10295684T9 Verfahren zum spezifischen Hemmen von Histon-Deacetylase-4 Method for the specific inhibition of histone deacetylase 4 |
| 10/14/2004 | CA2734606A1 Polypeptide comprising cell adhesion motif, t cell epitope and b cell epitope for inducing antibody production |
| 10/14/2004 | CA2561840A1 Use of pediocin a for the amelioration of digestive functionality |
| 10/14/2004 | CA2521410A1 Inhibitor proteins of a protease and use thereof |
| 10/14/2004 | CA2521221A1 Method for the treatment of prostate cancer |
| 10/14/2004 | CA2520582A1 Composition for the prevention and treatment of cellulitis |
| 10/14/2004 | CA2520580A1 Histamine binding compounds for treatment method for disease conditions mediated by neutrophils |
| 10/14/2004 | CA2520460A1 Use of fgf- 18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation |
| 10/14/2004 | CA2520406A1 Cxcr4 antagonists and methods of their use |
| 10/14/2004 | CA2520400A1 Treatment of aspergillus infections with thymosin alpha 1 |
| 10/14/2004 | CA2520392A1 Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding |
| 10/14/2004 | CA2520372A1 Stq-peptides |
| 10/14/2004 | CA2519998A1 Topical l-carnitine compositions |
| 10/14/2004 | CA2519803A1 Use of erythropoietin in stroke recovery |
| 10/14/2004 | CA2518903A1 Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant |
| 10/14/2004 | CA2517487A1 Inhibitors of phosphodiesterases in infertility |
| 10/14/2004 | CA2464175A1 Methods and compositions for modulating proteins modified in preconditioning against ischemia/hypoxia |
| 10/13/2004 | EP1466975A1 Postsynaptic proteins |
| 10/13/2004 | EP1466917A1 Method for making peptide boronic acids and acids obtainable thereby |
| 10/13/2004 | EP1466916A1 Peptide boronic acids useful in making salts thereof |
| 10/13/2004 | EP1466888A1 Calcium receptor-active arylalkyl amines |
| 10/13/2004 | EP1466649A1 Pharmaceutical composition containing artificial oxygen carrier |
| 10/13/2004 | EP1466626A1 Medicinal compositions for improving oral absorption |
| 10/13/2004 | EP1466624A1 Drug for regenerating tissue and vessel and method therefor |
| 10/13/2004 | EP1466621A1 Compositions for improving lipid metabolism |
| 10/13/2004 | EP1466620A1 Compounds modulating FSHR and therapeutic uses thereof |
| 10/13/2004 | EP1466619A2 Method for modulating cell apoptosis |
| 10/13/2004 | EP1466618A1 Treatment for diabetes |
| 10/13/2004 | EP1466616A2 Use of CASB616 polypeptides and polynucleotides for cancer treatment |
| 10/13/2004 | EP1466615A1 Pharmaceutical composition |
| 10/13/2004 | EP1466614A1 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon |
| 10/13/2004 | EP1466613A1 Compositions for mucosal and oral administration comprising hCG fragments |
| 10/13/2004 | EP1466612A1 Treatment of inflammation and sepsis with hCG derived peptides |
| 10/13/2004 | EP1466611A1 Use of HCG derived peptides in the treatment of iatrogenic diseases |
| 10/13/2004 | EP1466610A1 Medicinal compositions for nasal absorption |
| 10/13/2004 | EP1466607A1 Compositions for the treatment of primary and metastatic neoplastic diseases using arsenic compounds in combination with all-trans retinoic acid |
| 10/13/2004 | EP1466529A1 Composition with heart rate reducing properties |